About us

Our Mission Statement

Our mission is to bring meaningful, life-changing treatment options to people living with depression, especially those who do not benefit from today’s standards of care. We aim to advance fast-acting antidepressant therapies that can provide relief when time matters most, while maintaining the rigor, safety mindset, and development discipline required to translate science into real-world impact.

THE PROBLEM

Depression

Risk of Suicide:

Depression is a leading cause of Suicide

7% Adults

Over 17 million people in US had sever depression episode.

Economic Consequences

economic burden of depression in the US was estimated to be over $210 billion in 2019

THE SOLUTION

New generation antidepressant Biologics

EvoDenovo is advancing a precision biologics platform for depression and other CNS disorders, centered on engineered single-domain antibodies. By combining selectivity, modular engineering, and a development strategy built for speed and discipline, we aim to generate therapies that are both scientifically differentiated and operationally executable. The result is a biologic approach designed to translate compelling neuroscience into practical, scalable treatment options for patients who remain poorly served by current care.

THE SCIENCE

mGlyR and Depression

EvoDenovo’s science centers on GPR158, recently identified as a metabotropic glycine receptor (mGlyR): glycine binds an extracellular Cache domain and modulates a noncanonical signaling axis built around the RGS7–Gβ5 complex, with downstream effects on cAMP and cortical neuronal excitability. In the prefrontal cortex, GPR158 is reported to be upregulated in major depressive disorder, and in mice chronic stress increases GPR158 in a glucocorticoid-dependent manner; overexpression induces depressive-like behavior, while loss of GPR158 produces an antidepressant-like phenotype and stress resilience.

OUR PIPELINE

Scientific Advisory Board

Board

Contact us

For more information about EvoDenovo please contact us today using the form below:

    Collaborators